Skip to main content
SpringerLink
Log in

Inclusion body myositis: Review of recent literature

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Inclusion body myositis (IBM) is a progressive inflammatory skeletal muscle disease of unknown cause and without effective treatment. This article discusses existing literature, emphasizing disease mechanisms and models. In particular, it addresses limitations in the β-amyloid-mediated theory of IBM myofiber injury, flawed rationales of animal models of this disease, and recent reports regarding treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Chou SM: Myxovirus-like structures in a case of human chronic polymyositis. Science 1967, 158:1453–1455.

    Article  PubMed  CAS  Google Scholar 

  2. Yunis EJ, Samaha FJ: Inclusion body myositis. Lab Invest 1971, 25:240–248.

    PubMed  CAS  Google Scholar 

  3. Needham M, Mastaglia FL: Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007, 6:620–631.

    Article  PubMed  Google Scholar 

  4. Needham M, James I, Corbett A, et al.: Sporadic inclusion body myositis: phenotypic variability and influence of HLADR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 2008, 79:1056–1060.

    Article  PubMed  CAS  Google Scholar 

  5. Amato AA, Gronseth GS, Jackson CE, et al.: Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996, 40:581–586.

    Article  PubMed  CAS  Google Scholar 

  6. Griggs RC, Askanas V, DiMauro S, et al.: Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705–713.

    Article  PubMed  CAS  Google Scholar 

  7. Badrising UA, Maat-Schieman M, van Duinen SG, et al.: Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000, 55:1385–1387.

    PubMed  CAS  Google Scholar 

  8. Hoogendijk JE, Amato AA, Lecky BR, et al.: 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004, 14:337–345.

    Article  PubMed  Google Scholar 

  9. Chahin N, Engel AG: Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008, 70:418–424.

    Article  PubMed  Google Scholar 

  10. Quartuccio L, De Marchi G, Scott CA, et al.: Treatment of inclusion body myositis with cyclosporin-A or tacrolimus: successful long-term management in patients with earlier active disease and concomitant autoimmune features. Clin Exp Rheumatol 2007, 25:246–251.

    PubMed  CAS  Google Scholar 

  11. Felice KJ, Relva GM, Conway SR: Further observations on forearm flexor weakness in inclusion body myositis. Muscle Nerve 1998, 21:659–661.

    Article  PubMed  CAS  Google Scholar 

  12. Johnson L, Edwards D, Walters S, et al.: The effectiveness of an individualized, home-based functional exercise program for patients with sporadic inclusion body myositis. J Clin Neuromuscul Dis 2007, 8:187–194.

    Article  Google Scholar 

  13. Dalakas MC: Interplay between inflammation and degeneration: Using inclusion body myositis to study “neuroinflammation.” Ann Neurol 2008, 64:1–3.

    Article  PubMed  Google Scholar 

  14. Wilson FC, Ytterberg SR, St Sauver JL, Reed AM: Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol 2008, 35:445–447.

    PubMed  Google Scholar 

  15. Hatanaka Y, Oh SJ: Single-fiber electromyography in sporadic inclusion body myopathy. Clin Neurophysiol 2007, 118:1563–1568.

    Article  PubMed  Google Scholar 

  16. Barkhaus PE, Nandedkar SD: Serial quantitative electrophysiologic studies in sporadic inclusion body myositis. Electromyogr Clin Neurophysiol 2007, 47:97–104.

    PubMed  CAS  Google Scholar 

  17. Badrising UA, Verschuuren JJ, Wintzen AR, van Dijk JG: Synaptic dysfunction does not contribute to muscle weakness in inclusion-body myositis. Muscle Nerve 2007, 35:266–267.

    Article  PubMed  Google Scholar 

  18. Jackson CE, Barohn RJ, Gronseth G, et al.: Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve 2008, 37:473–476.

    Article  PubMed  CAS  Google Scholar 

  19. Needham M, Hooper A, James I, et al.: Apolipoprotein epsilon alleles in sporadic inclusion body myositis: a reappraisal. Neuromuscul Disord 2008, 18:150–152.

    Article  PubMed  Google Scholar 

  20. Greenberg SA: Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007, 69:2008–2019.

    Article  PubMed  Google Scholar 

  21. Needham M, Mastaglia FL: Sporadic inclusion body myositis: a continuing puzzle. Neuromuscul Disord 2008, 18:6–16.

    Article  PubMed  CAS  Google Scholar 

  22. Askanas V, Engel WK: Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol 2007, 19:550–559.

    Article  PubMed  Google Scholar 

  23. Greenberg SA: A gene expression approach to study perturbed pathways in myositis. Curr Opin Rheumatol 2007, 19:536–541.

    Article  PubMed  Google Scholar 

  24. Askanas V, Engel WK: Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 2006, 66:S39–S48.

    Article  PubMed  CAS  Google Scholar 

  25. Sarkozi E, Askanas V, Johnson SA, et al.: Beta-amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Neuroreport 1993, 4:815–818.

    Article  PubMed  CAS  Google Scholar 

  26. Askanas V, Sarkozi E, Bilak M, et al.: Human muscle macrophages express beta-amyloid precursor and prion proteins and their mRNAs. Neuroreport 1995, 6:1045–1049.

    Article  PubMed  CAS  Google Scholar 

  27. Sarkozi E, Askanas V, Johnson SA, et al.: Expression of beta-amyloid precursor protein gene is developmentally regulated in human muscle fibers in vivo and in vitro. Exp Neurol 1994, 128:27–33.

    Article  PubMed  CAS  Google Scholar 

  28. Greenberg SA, Sanoudou D, Haslett JN, et al.: Molecular profiles of inflammatory myopathies. Neurology 2002, 59:1170–1182.

    PubMed  CAS  Google Scholar 

  29. Schmidt J, Barthel K, Wrede A, et al.: Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008, 131:1228–1240.

    Article  PubMed  Google Scholar 

  30. Askanas V, Alvarez RB, Engel WK: Beta-amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol 1993, 34:551–560.

    Article  PubMed  CAS  Google Scholar 

  31. Choi YC, Park GT, Kim TS, et al.: Sporadic inclusion body myositis correlates with increased expression and crosslinking by transglutaminases 1 and 2. J Biol Chem 2000, 275:8703–8710.

    Article  PubMed  CAS  Google Scholar 

  32. Haass C, Schlossmacher MG, Hung AY, et al.: Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359:322–325.

    Article  PubMed  CAS  Google Scholar 

  33. Howland DS, Trusko SP, Savage MJ, et al.: Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J Biol Chem 1998, 273:16576–16582.

    Article  PubMed  CAS  Google Scholar 

  34. Leclerc A, Tome FM, Fardeau M: Ubiquitin and betaamyloid-protein in inclusion body myositis (IBM), familial IBM-like disorder and oculopharyngeal muscular dystrophy: an immunocytochemical study. Neuromuscul Disord 1993, 3:283–291.

    Article  PubMed  CAS  Google Scholar 

  35. Sherriff FE, Joachim CL, Squier MV, Esiri MM: Ubiquitinated inclusions in inclusion-body myositis patients are immunoreactive for cathepsin D but not beta-amyloid. Neurosci Lett 1995, 194:37–40.

    Article  PubMed  CAS  Google Scholar 

  36. Nalbantoglu J, Karpati G, Carpenter S: Conspicuous accumulation of a single-stranded DNA binding protein in skeletal muscle fibers in inclusion body myositis. Am J Pathol 1994, 144:874–882.

    PubMed  CAS  Google Scholar 

  37. Lunemann JD, Schmidt J, Schmid D, et al.: Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol 2007, 61:476–483.

    Article  PubMed  CAS  Google Scholar 

  38. Chou SM: Myxovirus-like structures and accompanying nuclear changes in chronic polymyositis. Arch Pathol 1968, 86:649–658.

    PubMed  CAS  Google Scholar 

  39. Greenberg SA, Pinkus JL, Amato AA: Nuclear membrane proteins are present within rimmed vacuoles in inclusionbody myositis. Muscle Nerve 2006, 34:406–416.

    Article  PubMed  CAS  Google Scholar 

  40. Greenberg SA, Watts GD, Kimonis VE, et al.: Nuclear localization of valosin-containing protein in normal muscle and muscle affected by inclusion-body myositis. Muscle Nerve 2007, 36:447–454.

    Article  PubMed  CAS  Google Scholar 

  41. Nakano S, Shinde A, Fujita K, et al.: Histone H1 is released from myonuclei and present in rimmed vacuoles with DNA in inclusion body myositis. Neuromuscul Disord 2008, 18:27–33.

    Article  PubMed  Google Scholar 

  42. Greenberg SA, Bradshaw EM, Pinkus JL, et al.: Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005, 65:1782–1787.

    Article  PubMed  CAS  Google Scholar 

  43. Bradshaw EM, Orihuela A, McArdel SL, et al.: A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007, 178:547–556.

    PubMed  CAS  Google Scholar 

  44. Greenberg SA, Pinkus GS, Amato AA, Pinkus JL: Myeloid dendritic cells in inclusion-body myositis and myositis and polymyositis. Muscle Nerve 2007, 35:17–23.

    Article  PubMed  CAS  Google Scholar 

  45. Salajegheh M, Rakocevic G, Raju R, et al.: T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis. Neurology 2007, 69:1672–1679.

    Article  PubMed  CAS  Google Scholar 

  46. De Paepe B, Creus KK, De Bleecker JL: Chemokine profile of different inflammatory myopathies reflects humoral versus cytotoxic immune responses. Ann N Y Acad Sci 2007, 1109:441–453.

    Article  PubMed  Google Scholar 

  47. Salajegheh M, Raju R, Schmidt J, Dalakas MC: Upregulation of thrombospondin-1 (TSP-1) and its binding partners, CD36 and CD47, in sporadic inclusion body myositis. J Neuroimmunol 2007, 187:166–174.

    Article  PubMed  CAS  Google Scholar 

  48. Walsh RJ, Kong SW, Yao Y, et al.: Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007, 56:3784–3792.

    Article  PubMed  CAS  Google Scholar 

  49. Dalakas MC: Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 1998, 55:1509–1512.

    Article  PubMed  CAS  Google Scholar 

  50. Greenberg SA: Comment on ‘Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle.’ Brain 2008 Jul 24 (Epub ahead of print).

  51. Hutchinson DO, Jongbloed B: Two-dimensional gel electrophoresis in inclusion body myositis. J Clin Neurosci 2008, 15:440–444.

    Article  PubMed  CAS  Google Scholar 

  52. Kannanayakal TJ, Mendell JR, Kuret J: Casein kinase 1 alpha associates with the tau-bearing lesions of inclusion body myositis. Neurosci Lett 2008, 431:141–145.

    Article  PubMed  CAS  Google Scholar 

  53. Macaione V, Aguennouz M, Mazzeo A, et al.: Expression of transglutaminase 2 does not differentiate focal myositis from generalized inflammatory myopathies. Acta Neurol Scand 2008, 117:393–398.

    Article  PubMed  CAS  Google Scholar 

  54. Choi YC, Kim TS, Kim SY: Increase in transglutaminase 2 in idiopathic inflammatory myopathies. Eur Neurol 2004, 51:10–14.

    Article  PubMed  CAS  Google Scholar 

  55. Wojcik S, Engel WK, Yan R, et al.: NOGO is increased and binds to BACE1 in sporadic inclusion-body myositis and in A beta PP-overexpressing cultured human muscle fibers. Acta Neuropathol 2007, 114:517–526.

    Article  PubMed  CAS  Google Scholar 

  56. Terracciano C, Nogalska A, Engel WK, et al.: In inclusion-body myositis muscle fibers Parkinson-associated DJ-1 is increased and oxidized. Free Radic Biol Med 2008, 45:773–779.

    Article  PubMed  CAS  Google Scholar 

  57. Fukuchi K, Pham D, Hart M, et al.: Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. Am J Pathol 1998, 153:1687–1693.

    PubMed  CAS  Google Scholar 

  58. Jin LW, Hearn MG, Ogburn CE, et al.: Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis. Am J Pathol 1998, 153:1679–1686.

    PubMed  CAS  Google Scholar 

  59. Kitazawa M, Green KN, Caccamo A, LaFerla FM: Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol 2006, 168:1986–1997.

    Article  PubMed  CAS  Google Scholar 

  60. Moussa CE, Fu Q, Kumar P, et al.: Transgenic expression of beta-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology. FASEB J 2006, 20:2165–2167.

    Article  PubMed  CAS  Google Scholar 

  61. Strazielle C, Dumont M, Fukuchi K, Lalonde R: Transgenic mice expressing the human C99 terminal fragment of betaAPP: effects on cytochrome oxidase activity in skeletal muscle and brain. J Chem Neuroanat 2004, 27:237–246.

    Article  PubMed  CAS  Google Scholar 

  62. Sugarman MC, Kitazawa M, Baker M, et al.: Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. Neurobiol Aging 2006, 27:423–432.

    Article  PubMed  CAS  Google Scholar 

  63. Sugarman MC, Yamasaki TR, Oddo S, et al.: Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A 2002, 99:6334–6339.

    Article  PubMed  CAS  Google Scholar 

  64. Capsoni S, Ruberti F, Di Daniel E, Cattaneo A: Muscular dystrophy in adult and aged anti-NGF transgenic mice resembles an inclusion body myopathy. J Neurosci Res 2000, 59:553–560.

    Article  PubMed  CAS  Google Scholar 

  65. Chen X, Ghribi O, Geiger JD: Rabbits fed cholesterolenriched diets exhibit pathological features of inclusion body myositis. Am J Physiol Regul Integr Comp Physiol 2008, 294:R829–R835.

    PubMed  CAS  Google Scholar 

  66. Delaunay A, Bromberg KD, Hayashi Y, et al.: The ER-bound RING finger protein 5 (RNF5/RMA1) causes degenerative myopathy in transgenic mice and is deregulated in inclusion body myositis. PLoS ONE 2008, 3:e1609.

    Article  PubMed  Google Scholar 

  67. Kitazawa M, Trinh DN, Laferla FM: Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 2008, 64:15–24.

    Article  PubMed  CAS  Google Scholar 

  68. University of California: Lithium chloride slows onset of skeletal muscle disorder [press release]. Available at http://www.universityofcalifornia.edu/news/article/17499. Accessed November 14, 2008.

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA, 02115, USA

    Steven A. Greenberg

Authors
  1. Steven A. Greenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven A. Greenberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Greenberg, S.A. Inclusion body myositis: Review of recent literature. Curr Neurol Neurosci Rep 9, 83–89 (2009). https://doi.org/10.1007/s11910-009-0013-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-009-0013-x

Keywords

Search

Navigation